RE:RE:Subaru1, before I head out, Mr. Pidduck clearly used the Fair enough but the CEO also mentioned their inability to reveal their "traditional global pharmaceutical partner" FOR COMPETITIVE REASONS.
Those last three words indicates very clearly commercial development that is not yet available to be released publicly. You can go back and check out that fact for yourself by listening towards the end of one of the conference calls of late 2022 or early 2023.
And that okgonow is a recorded fact and one needs to correlate that statement to another statement made on the public of "over 20 strong clinical trials, many in late stage".
This to me is an indication that they have been working with their global pharma partner for quite some time, perhaps several years from the past. That you can extrapolate from 'many in late stage' if you can approximate how long it takes for Stage 1 and Stage 2 clinical trials to be completed before going Stage 3.
So we are trying to keep it 'very real' based on FACTS disclosed publicly to us as shareholders by the CEO and other members of senior managment.
Have a wonderful evening, Peace and Tranquility π.